Liposome-mediated peptide loading of MHC-DR molecules in vivo  by 't Hart, Bert A. et al.
FEBS 18638 FEBS Letters 409 (1997) 91-95 
Liposome-mediated peptide loading of MHC-DR molecules in vivo 
Bert A. 't Harta,c'*, Diënne G. Elferinkb, Jan Wouter Drijfhoutb, Gert Stormc, 
Louis van Blooijsc, Ronald E. Bontropa'b, René R.P. de Vriesb 
aDepartment of Immunobiology, Biomédical Primate Research Centre, P. O. Box 3306, 2280 GH Rijswijk, The Netherlands 
hDepartment of Immunohematology and Blood Bank, University Hospital, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands 
' Department of Pharmaceutics, Faculty of Pharmacy, Utrecht University, Sorhonnelaan 16, 3584 CA Utrecht, The Netherlands 
Received 7 April 1997 
Abstract Amino acid residues 3-15 of mycobacterial HSP60 
define a dominant T-cell epitope for HLA-DR3+ve humans and 
Mamu-DR3+ve rhesus monkeys. Our results show that Matnu-
DR3 molecules on PBMC can be efficiently loaded in vivo with 
the above-mentioned peptides when they are intravenously 
injected encapsulated in liposomes, but not in the free form. 
Mamu-DR3 loading is abolished by encapsulation of a 
nonstimulatory peptide. These results have implications for the 
delivery of therapeutic peptides in vivo. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
T-cell recognition of antigens which are presented in the 
context of MHC class II molecules is a key-process in normal 
and pathological processes of the immune system [1,2]. Inter-
ference in the recognition process with competitor peptides 
(CP) such as nonstimulatory analogues of T-cell stimulatory 
peptides (SP) is regarded as a specific approach for therapy of 
autoimmune diseases [3]. Indeed promising results have been 
obtained in disease models, such as autoimmune encephalo-
myelitis, in inbred strains of mice and rats [4,5]. However, 
data in outbred species such as nonhuman primates, which 
are phylogenetically closely related to humans, are scarce. 
In the present study we have investigated the in vivo load-
ing of rhesus monkey Mamu-DR3 molecules with peptides 
derived from the 65 kDa heat-shock protein (HSP65) of My-
cobacterium tuberculosis. The overlapping peptides HSPp3-13 
and HSPp4-15 were used as SP since they contain an immu-
nodominant T-cell epitope in HLA-DR3 positive individuals 
[6,7] and also for the evolutionary equivalent molecules in 
rhesus monkeys, named Mamu-DR3 [8]. A nonstimulatory 
variant peptide of p4-15 (p4-15 E->R), which binds with 
the same kinetics to Mamu-DR3 as SP and therefore prevents 
the loading of SP and subsequent T-cell stimulation in vitro 
[9], was selected as CP. 
The SP-Mamu-DR3 complex is recognized by several SP-
specific and HLA-DR3-restricted human T-cell clones [8]. This 
phenomenon of trans-species presentation of antigen to hu-
*Fax: (31) 15-284-3999. 
E-mail: hart@bprc.nl 
Abbreviations: HSP, heat-shock protein; CP, competitor peptide; 
MHC, major histocompatibility complex (HLA in man; Mamu in 
rhesus monkey); PBMC, peripheral blood mononuclear cell(s); SP, 
stimulatory peptide 
man T cells has been demonstrated also with APC from other 
nonhuman primate species in combination with various anti-
gens [10-12]. This principle enabled us to monitor the in vivo 
loading of Mamu-DR3 molecules in rhesus monkeys by pro-
liferation-induction of the cross-reactive HLA-DR3 restricted 
human T-cell clones. 
The aim of this study was to investigate the possibility of in 
vivo loading of Mamu-DR3 molecules with CP. Because CP 
does not stimulate the T-cell clones, we have first investigated 
loading of SP and then tested if loading of SP could be pre-
vented with CP. 
Our results show that after bolus injection of SP in the free 
form to a dose of 25 mg free SP is detectable in venous blood 
plasma but disappears rapidly from the circulation. PBMC 
isolated from the same blood samples failed to activate the 
T-cell clones indicating that loading of Mamu-DR3 molecules 
with the SP at significant level had not taken place. A similar 
observation has been reported by Grey and co-workers, 
namely that in vivo administered peptides fail to load murine 
I-Ab molecule [13]. 
Similar experiments were performed with SP encapsulated 
in unselected liposomes. In this situation only low plasma 
levels of SP were found but PBMC isolated from the same 
blood samples displayed a high stimulatory capacity of the 
human T-cell clones. Even after injection of only 300 u.g of 
SP encapsulated in the liposomes significant stimulatory ca-
pacity of the PBMC was found. PBMC isolated after injection 
of liposomes which contained besides SP also CP, were unable 
to induce proliferation of the clones, indicating that loading of 
Mamu-DR3 molecules was abolished. These results show that 
rhesus monkeys can be used to investigate the conditions for 
in vivo loading of MHC class II molecules on APC. 
2. Materials and methods 
2.1. Animals 
Each animal in the pedigreed rhesus monkey colony at the Bioméd-
ical Primate Research Centre, which is located in Rijswijk, The Neth-
erlands, has been typed for most known MHC class I and II mole-
cules. For inclusion in the present study PBMC from a panel of 
Mamu-DR3-positive monkeys was tested for the capacity to present 
the SP to a set of p3-13-specific and HLA-DR3-restncted T-cell clones 
[7,8]. Two high responder monkeys (IRA, female, birth August 1983; 
and 4051, male, birth December 1988) were selected on these criteria. 
Both monkeys lacked antibodies and a proliferative T-cell response to 
the SP. 
The experiments reported here have been approved by the Insti-
tute's Animal Care and User Committee. 
2.2. Antigens 
Peptides were synthesized by solid-phase strategies on an automated 
multiple peptide synthesizer at 48 X 10 umol scale (Abimed AMS 422) 
[14] using TentagelS AC as a resin (Rapp, Tübingen, Germany) [15]. 
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Repetitive couplings were performed by adding a mixture of 90 ul of 
0.67 M PyBOP (benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium 
hexafluorophosphate [14] in NMP (A'-methylpyrrolidone), 20 ul of 
NMM (JV-methylmorpholine) in NMP 2/1 (v/v) and 100 ul of a 
0.60 M solution of the appropriate Fmoc (9-fluorenylmethoxycarbon-
yl) amino acids [16,17] in NMP (6-fold excess) to each reaction vessel. 
At 70% of the reaction time approximately 50 ul of dichloromethane 
was added to each reaction vessel. Fmoc-deprotection was performed 
by adding 3 times 0.8 ml of piperidine/DMA (A^Af-dimethylaceta-
mide) 1/4 (v/v) to each reaction vessel. Coupling and deprotection 
times were increased as the synthesis proceeded, starting with 60 
min and 3 times 3 min, respectively. Washing after coupling and 
Fmoc deprotection steps were done with 6 times 1.2 ml of DMA. 
Cleavage of the peptides was performed with TFA (trifluoroacetic 
acid)/water 19/1 (v/v) for 3 h. Peptides were collected by ether precip-
itation, dissolved in water, centrifugated and lyophilized. Quantitation 
was done by OD measurement at 276 nm using Ey = 1400. The purity 
of the peptides was determined by analytical reversed phase HPLC 
using a water-acetonitrile gradient containing 0.1% TFA and proved 
to be always greater than 90% (UV at 214 nm). The integrity of the 
peptides was determined by laser-desorption time-of-flight mass spec-
trometry (TOF-MALDI) on a Lasermat mass spectrometer (Finnigan 
MAT, UK) using ACH (a-cyano-4-hydroxycinnamic acid; 10 mg/ml 
in acetonitrile/water 60/40 v/v) containing 0.1% as a matrix. Calibra-
tion was performed with a peptide of known molecular mass as in-
ternal reference. 
Three peptides were synthesized: (i) p3-13 (KTIAYDEEARR); (ii) 
protected p4-15 (TIAYDEEARRGL-NH2) and (iii) a p4-15 analogue 
which fails to activate the T-cell clones used in this study as conse-
quence of a E->R substitution at position 9 (TIAYDREARRGL-
NH2), which is one of three TCR contacting residues. All three pep-
tides bind to HLA- and Mamu-DR3 molecules due to the presence of 
the motif -I(AY)D- [8]. To date, identical results have been obtained 
when wither p3-13 or p4-15 were used as SP of the human clones. 
Prepulse experiments have shown that the nonstimulatory p4-15 ana-
logue interferes only with binding of p4-15 to the Mamu-DR3 mole-
cule but not with binding to the TCR. 
2.3. Liposome preparation 
Partially hydrogenated egg-phosphatidylcholine with an iodine val-
ue of 40 (PHEPC) was purchased from Asahi Chemical Industry Co. 
Ltd. (Ibarakiken, Japan). Egg-phosphatidylcholesterol (EPG) was ob-
tained from Lipoid (Ludwigshafen, Germany). Cholesterol (Choi) was 
from Sigma Chem. Co. (St. Louis, MO). A lipid mixture of PHEPC/ 
EPG/Chol (10:1:4 molar ratio) was prepared in chloroform/methanol 
(10:1) and dried to a thin film by rotary evaporation. After evacua-
tion for at least 1 h the lipid film was hydrated in HEPES buffer (50 
mM HEPES, 73 mM NaCl, pH 8.0; 1 mmol phospholipid/ml) con-
taining effector peptide (1.6 mg/ml) and/or competitor peptide (62.5 
mg/ml). Nonentrapped peptide was removed by ultracentifugation at 
160 000 X g during 30 min. After décantation of the supernatant the 
pellet was resuspended and subsequently washed 4 times with HEPES 
buffer (10 mM HEPES, 140 mM NaCl, pH 7.4). The dispersions were 
diluted with 10 mM HEPES buffer to a final phospholipid concen-
tration of 0.2 mmol/ml. The final peptide-to-phospholipid ratio of the 
dispersions amounted to 1.1 mg/mmol in case of SP liposome formu-
lations, 23.7 mg/mmol in case of the CP liposome formulation and 
0.54 and 21.3 mg/mmol, respectively, for the liposomes containing 
both effector and competitor peptide. Liposome dispersions were 
stored at 4°C under nitrogen atmosphere for maximally 1 week. 
2.4. Test substance administration and blood sampling 
Test substance administration and blood sampling were performed 
in fully conscious monkeys, which were placed in a restraint chair. 
The method was chosen because repeated sedation could avoided. 
When appropriately trained before starting the experiment, this pro-
cedure causes only negligible inconvenience to the monkeys. Test sub-
stances were injected as bolus into the vena saphena and blood sam-
ples were collected in heparinized vacutainer tubes from the vena 
saphena in the contralateral leg. 
2.5. Experimental design 
Just before and at different time points after test-substance admin-
istration venous blood samples were collected. Plasma and blood cells 
were separated by centrifugation for 10 min at 200 Xg. After collect-
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ing plasma, the pelleted cells were resuspended in PBS and PBMC 
were isolated by density gradient centrifugation on Lymphocyte Sep-
aration Medium (LSM: Organon-Technika Corp., Durham, NC) for 
25 min at 280Xg. Isolated PBMC were washed twice with PBS, re-
suspended in RPMI containing 10% pooled human serum and kept 
stored at 4°C until testing for proliferation induction of T-cell clones. 
2.6. T-cell clones 
Three p3-13 specific and HLA-DR3 restricted human T-cell clones 
(CAA pl51-l, DAA pl51-l and DAA pl51-2) were used [7]. Prolif-
eration was assayed by mixing 104 T cells with 5X104 irradiated 
PBMC (50 Gy) as APC in 96-well flatbottom microtiter plates in 
triplicate. After 66 h of culture, 0.5 uCi [3H]thymidine (NEN Dupont; 
6.7 mCi/ml specific activity) was added to each well and 18 h later 
cells were collected on glass filters. To determine incorporation of 
radiolabel, DNA was precipitated on glass filters and 3H levels were 
measured by liquid scintillation counting. 
2.7. Measurement of SP levels in plasma 
T-cell clones were cultured with irradiated PBMC from a HLA-
£>i?i-matched human donor as APC. Rhesus monkey plasma samples 
were added to the cultures as antigen source to a final concentration 
of 10% (v/v). In parallel cultures logarithmic dilutions of SP were 
added. Proliferation was determined as described above. 
2.8. Measurement of SP and CP presentation by PBMC 
PBMC were isolated from the rhesus monkey venous blood sam-
ples, irradiated at 50 Gy and cultured with the three T-cell clones. 
Proliferation was measured as described above. 
CP loading in the Mamu-DPJ molecules was measured indirectly 
namely by inhibition of SP presentation, as described above. For 
effective blocking of SP presentation in culture 100-fold excess of 
CP is needed [9]. Because the maximal amount of peptide that could 
be entrapped in the administered volume of liposomes (5 ml) proved 
to be 30 mg the following liposomes containing 30 mg CP, 0.3 mg SP 
or 30 mg CP +0.3 mg SP were prepared. 
2.9. Normalization of the results 
The substantial day-to-day variation of the proliferative response of 
the T-cell clones to the SP under standard conditions necessitated 
normalization of results. For normalization, cpm measured in parallel 
cultures of the clones stimulated with 1 |ig SP and human APC were 
set at 100%. The cpm from cultures belonging to the same series are 
expressed as percentage of this control value. 
3. Results and discussion 
3.1. Intravenous injection of free SP 
To determine whether intravenously injected SP binds to 
Mamu-DR3 molecules in vivo, a rhesus monkeys were injected 
with three consecutive doses of 1, 5 and 25 mg SP at 1 h 
interval. Venous blood samples were collected at 2, 5, 10 
and 60 min after each injection and the presence of SP in 
plasma or bound to PBMC was assayed by stimulation of 
the human T-cell clones. As shown by the typical example 
depicted in Fig. 1, no significant stimulatory activity of 
PBMC was found. Analysis of the plasma fraction of the 
blood samples using human APC shows presence of SP, which 
remained detectable for at least 10 min after injection. It is 
therefore concluded that effective loading of MHC-DR mole-
cules on PBMC with intravenously injected SP in the free 
form did not take place. 
In a 3 day culture of rhesus monkey PBMC with the human 
T-cell clones a SP concentration of less than 1 (ig/ml is suffi-
cient to induce loading of Mamu-DR3 molecules on the 
PBMC as deduced from proliferation of the T cells. A SP 
dose of 25 mg given to a monkey of 5 kg with a blood volume 
of about 300 ml results in a theoretical plasma concentration 
of about 75 |Xg/ml. Consequently absence of Mamu-DR3 load-
ing with injected free SP is likely not due to insufficient plas-
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Fig. 1. SP levels in plasma and bound to PBMC when injected as free peptide. Rhesus monkey IRA was injected with three consecutive doses 
of free SP: 1 mg (t = 0), 5 mg (t = 75 min) and 25 mg (t = 150 min). At the indicated time points venous blood samples were collected and plas-
ma and PBMC were separated by centrifugation. The SP levels in plasma (white bars) were determined by proliferation-induction of the T-cell 
clones with human APC and 10% plasma (open bars) as antigen source. Cell-bound SP (closed bars) was determined by culturing the T-cell 
clones with irradiated monkey PBMC. Proliferation assays were performed as described in Section 2. The results obtained with T-cell clone 
CAApl51-l are shown as representative example. Normalization of the results was performed as described in Section 2. 
ma levels. A more plausible explanation is that pharmacoki-
netic properties of the peptide are too poor for efficient bind-
ing to the relevant MHC class II molecules. A similar con-
clusion has been reached based on experiments in mice [13]. 
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3.2. Intravenous injection of liposome-encapsulated SP 
Encapsulation of SP into liposomes may prolong the blood 
circulation time of the peptide and enhance uptake by blood 
monocytes [18,19]. Importantly, ingested particles arrive in the 
phagolysomes, being a cell compartment where degradation of 
the particles and loading of MHC class II molecules may take 
place [25]. To investigate this possibility, two monkeys were 
intravenously injected with a single liposome dose containing 
2.5 mg SP. At 1, 2, 4 and 8 h after injection, plasma and 
PBMC were collected and again assayed for the presentation 
of SP by proliferation-induction of the T cell clones. The 
results in Fig. 2 show that PBMC collected at 1 and 2 h after 
injection of liposome-encapsulated SP stimulate proliferation 
of the T-cell clones, whereas only negligible stimulatory activ-
ity was found in the plasma. This experiment clearly demon-
strates that liposome-encapsulation of SP facilitates loading of 
Mamu-DR molecules on PBMC. 
In a next experiment the dose-effect relationship and the 
time course of Mamu-DR3 loading with SP were further in-
vestigated. One monkey was injected at 3 h intervals with 
liposomes containing 0.3, 1.0 and 3.0 mg SP, respectively. 
Fig. 2. SP levels in plasma and bound to PBMC upon injection of 
SP containing liposomes. Rhesus monkey 4051 was injected with 
5 ml of liposome suspension containing 2.5 mg SP. At 1, 2, 4 and 
8 h after injection venous blood samples of 2.5 ml each were col-
lected. Plasma and cells were separated by centrifugation. Loading 
of PBMC with SP (closed bars) or SP activity in plasma (open 
bars) was assayed. The SP levels in plasma were determined by pro-
liferation-induction of the T-cell clones with human APC and 10% 
plasma as antigen source. Cell-bound SP (closed bars) was deter-
mined by culturing the T-cell clones with irradiated monkey PBMC. 
The results obtained with monkey 4051 and T-cell clone CAApl51-
1 as read-out system are shown as a representative example. Nor-
malization of the results was performed as described in Section 2. 
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Fig. 3. Dose-response relationship of i.v. injected liposome-encapsulated SP. Rhesus monkey 4051 was injected intravenously with three doses 
of SP-containing liposomes. At / = 0 h liposomes containing 0.3 mg SP were injected, followed by liposomes containing 1.0 mg SP at t = 3 h 
and liposomes containing 3.0 mg at t = 6 h. At 15 min and 1, 2 and 3 h after each injection venous blood samples were taken and PBMC or 
plasma were isolated. Loading of PBMC with SP was assayed as described in the legends to Fig. 2. The results obtained with clone CAApl51-
1 are shown as representative experiment. Normalization of the results was performed as described in Section 2. 
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Fig. 4. Effect of incorporation of the competitor peptide (CP) in the liposomes. On 3 consecutive days three liposome formulations were tested, 
each given as 5 ml bolus injections. Liposomes containing only 0.3 mg SP/5 ml suspension were injected at day 1. Liposomes containing 0.3 
mg SP and 30 mg CP were injected at day 2. Liposomes containing only 30 mg CP were injected at day 3. Loading of PBMC with SP was as-
sayed by proliferation induction of clone DAApl51-l. Normalization of the results was performed as described in Section 2. 
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At 15 min, 1, 2 and 3 h after each injection, plasma and 
PBMC were isolated and tested for proliferation-induction 
of the clones (Fig. 3). Interestingly, already at a dose of 0.3 
mg injected peptide significant proliferation of the clones was 
found. The maximal stimulatory capacity of the PBMC was 
found at 2 h after injection of the liposomes. Injection of 
liposomes with 1.0 or 3.0 mg SP resulted in higher and 
more sustained stimulatory capacity of the PBMC. 
3.3. Effect of CP on Mamu-DR3 binding of SP 
The results discussed thus far provide evidence that lipo-
somes may serve as a vehicle for targeting of peptide to 
MHC-DR antigens on APC. The nonstimulatory CP p4-
15(E > R) was found to abolish presentation of SP by com-
petitive inhibition of binding to HLA-DR3 in vitro. Mamu-
DR3 loading with CP in vivo was assessed indirectly, namely 
by inhibition of SP presentation by PBMC to the T-cell 
clones. It is known that a 100-fold higher concentration of 
CP than of SP in the culture medium is needed for complete 
inhibition of T-cell proliferation. Hence, SP was encapsulated 
with 100-fold excess CP in the liposomes. Two monkeys were 
injected at 3 consecutive days with the peptide-containing lip-
osomes and the stimulatory capacity of their PBMC was 
tested on clones CAApl51-l, DAApl51-l and DAApl51-2 
(Fig. 4). The figure shows that the sustained stimulatory ac-
tivity of PBMC isolated after injection of liposomes contain-
ing only SP is completely abolished by encapsulation of excess 
CP in the liposomes. This suggests that CP binds effectively to 
the Mamu-DR3 molecules and prevents binding of SP. As 
anticipated, no stimulatory activity of PBMC was found after 
injection of liposomes containing only CP. 
3.4. Conclusion 
Following the pioneering work of Adorini and coworkers 
on in vivo competition between self and foreign peptides for 
MHC binding [20], the use of synthetic peptides for specific 
therapy of autoimmune diseases has been assessed by many 
investigators. Promising data have been obtained especially in 
the two very well characterized murine autoimmune disease 
models, namely experimental autoimmune encephalomyelitis 
and collagen-induced arthritis [4,5,21-23]. The main conclu-
sion of the present study is that liposome-peptide prepara-
tions can be used for efficient delivery of peptides to the rel-
evant MHC class II molecules. The logic extension of our 
present study is to test if liposomes containing competitor 
peptides can be used to prevent or control disease in the 
rhesus monkey EAE model. Two main immune-response 
gene products, one Mamu-DP and one Mamu-DR molecule 
with their respective epitopes from the MBP molecule have 
been identified recently [12,24]. Such a study will reveal if 
peptide-mediated therapy of autoimmune disease is feasible 
in an outbred primate population and if a liposome formula-
tion can overcome the continuous supply of high peptide 
doses which are necessary for sustained saturation of the tar-
get MHC class II molecules [13,25]. 
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